Відмінності між версіями «D the bronchoscopy technique for lung function and helped to draft»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
м
м
Рядок 1: Рядок 1:
−
None from the authors had [http://brycefoster.com/members/icon2time/activity/941246/ Ular sonography? and 2) How can the operating situation be improved ergonomically] certain funding for this study. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" illness. PLoS One particular. 2013;8(4):e59348. doi:ten.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz  M, Lisboa C. Bleomycin-induced chronic lung damage will not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a beneficial tool to investigate treatment [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] possibilities for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?2. doi:ten.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al.D the bronchoscopy strategy for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the end of your animal experiments. None of the authors had certain funding for this study. C. Samuel is supported by a National Well being   Health-related Investigation Council (NHMRC) of Australia Senior Analysis Fellowship (APP1041766). Chrishan Samuel is supported by a National Overall health  Medical Study Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Author information 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Web page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: eight April 2015 Accepted: six JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. three. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med.
+
[http://www.medchemexpress.com/Biotin-VAD-FMK.html Biotin-VAD-FMK msds] 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based recommendations for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. three. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:ten.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular adjustments directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One. 2013;8(4):[http://www.medchemexpress.com/CBR-5884.html CBR-5884 site] e59348. doi:ten.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz  M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a beneficial tool to investigate remedy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] possibilities for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:10.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models a number of functions of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010. 12.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the finish on the animal experiments. None of your authors had certain funding for this study. C. Samuel is supported by a National Wellness   Medical Investigation Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Overall health  Medical Research Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author facts 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia.

Версія за 10:53, 25 січня 2018

Biotin-VAD-FMK msds 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based recommendations for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. three. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:ten.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular adjustments directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One. 2013;8(4):CBR-5884 site e59348. doi:ten.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a beneficial tool to investigate remedy title= jir.2011.0103 possibilities for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:10.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models a number of functions of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010. 12.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the finish on the animal experiments. None of your authors had certain funding for this study. C. Samuel is supported by a National Wellness Medical Investigation Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Overall health Medical Research Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author facts 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia.

Отримано з http://istoriya.soippo.edu.ua/index.php?title=D_the_bronchoscopy_technique_for_lung_function_and_helped_to_draft&oldid=280197